If you follow any wellness-focused social accounts, ashwagandha has probably shown up in your feed at least a dozen times this year. It’s in stress-relief gummies, sleep support blends, hormone-balance protocols, and pre-workout powders. Sales have grown steadily enough that the global market for this single herb now exceeds $500 million annually — and US consumers are among its biggest buyers.
But here’s what those glossy product pages rarely mention: over the past several years, a small but consistent pattern of liver injury reports has emerged among ashwagandha users. Enough of them that the U.S. Pharmacopeia (USP), one of the most trusted scientific bodies in the supplement industry, quietly added ashwagandha to its list of ingredients under hepatotoxicity review.
That doesn’t mean you need to throw out your bottle tonight. It does mean you should understand what the actual risk picture looks like — because the wellness industry isn’t exactly rushing to tell you.
How Serious Is the Liver Risk, Really?
Let’s put some context around this. Drug-induced liver injury (DILI) is notoriously hard to pin on a specific supplement, because most people take multiple products and liver conditions have many causes. But peer-reviewed case reports of ashwagandha-linked hepatotoxicity have now been published in journals including the Journal of Clinical and Experimental Hepatology, Annals of Internal Medicine, and JAMA Network Open. As of 2024, the published case literature included more than 20 individual reports of liver injury where ashwagandha was identified as the most probable causative agent.
The injury pattern in these cases is typically cholestatic — meaning bile flow from the liver is impaired — which presents as jaundice, dark urine, persistent fatigue, and elevated liver enzymes (ALT, AST, and bilirubin). In most documented cases, symptoms resolved after stopping the supplement. But in several severe cases, patients required hospitalization, and liver function took months to fully normalize.
The FDA collects this kind of data through its CFSAN Adverse Event Reporting System (CAERS), though reporting is voluntary and almost certainly undercounts actual incidents. What we can say is that multiple independent hepatologists have now described this pattern in the literature, and the USP’s decision to flag ashwagandha reflects a real signal — not a fringe concern.
To be clear: this herb has a 3,000-year history of use in Ayurvedic medicine at specific doses. The risk isn’t with ashwagandha itself. The risk is with how it’s being commercialized, concentrated, and consumed at scale in 2026.
Why Ashwagandha Products Vary So Dramatically — And Why It Matters
Here’s the part of this story that most consumers don’t know: not all ashwagandha is the same ingredient.
Withania somnifera (ashwagandha’s botanical name) contains an active compound group called withanolides — steroidal lactones that are responsible for most of the herb’s adaptogenic effects. But the plant’s root and its leaves contain very different profiles of these compounds, along with different alkaloid ratios. Root extract has the longest history of Ayurvedic use, typically at 300–600 mg/day. Leaf extracts are cheaper to produce, tend to carry higher withanolide concentrations, and appear more frequently in the case reports of liver injury.
When you look at what’s actually on US store shelves, the variation is striking. A review of commercial ashwagandha products found serving sizes ranging from 250 mg to over 1,500 mg per day — a six-fold difference — with no regulatory requirement that any of those doses be justified by clinical evidence. Some products carry proprietary designations like “KSM-66” or “Sensoril,” which are root-based, standardized extracts with published safety studies behind them. Others simply say “ashwagandha extract” with no indication of which plant part was used, how it was extracted, or what the withanolide percentage actually represents in practice.
The phrase “standardized to 5% withanolides” sounds reassuring, but it tells you almost nothing about batch-to-batch consistency, bioavailability, or which specific withanolide compounds are present.
The FDA does not require supplement manufacturers to prove safety or efficacy before products reach shelves. Under DSHEA — the Dietary Supplement Health and Education Act passed in 1994 — the burden of proof falls on the FDA to demonstrate a product is unsafe after the fact. Which means consumers are effectively the last line of defense, unless manufacturers voluntarily pursue third-party testing and certification.
Most don’t.
Who Faces the Highest Risk
The majority of people who take ashwagandha in the clinically studied dose range of 300–600 mg/day of root extract don’t experience liver issues. The risk appears meaningfully elevated in specific groups, and if you fall into any of these categories, this warrants real attention.
People with existing liver conditions. If your ALT or AST levels are already elevated — even mildly — adding a hepatotoxic botanical is a compounding factor. This matters more than most people realize: non-alcoholic fatty liver disease (NAFLD) affects an estimated 38% of American adults, and the majority of them don’t know it.
People with autoimmune thyroid conditions. Ashwagandha influences thyroid hormone production, and multiple case reports involve patients with pre-existing Hashimoto’s thyroiditis who developed liver inflammation. If you’re taking levothyroxine, methimazole, or another thyroid medication, this interaction deserves a conversation with your doctor before you add any ashwagandha product to your routine.
People stacking multiple supplements. Combining several botanical products simultaneously — ashwagandha alongside high-dose turmeric, green tea extract, berberine, or other liver-processed compounds — creates a cocktail that no published clinical study has actually evaluated. When something goes wrong in a polypharmacy situation, it’s genuinely difficult to identify the culprit, and that delay can matter when liver enzymes are rising.
People using high-dose or leaf-based extracts. Products that exceed 600 mg per serving, or those that use “whole plant extract,” “full-spectrum extract,” or simply don’t specify root-only sourcing, carry more uncertainty. That uncertainty cuts both ways: higher concentrations of withanolides might deliver stronger effects, but the safety ceiling hasn’t been established.
What to Look for When Buying Ashwagandha (If You Choose to Use It)
The goal here isn’t to scare you away from a botanical with a legitimate track record. It’s to give you the information to make an actually informed choice — because the product in most shopping carts right now isn’t the herb that Ayurvedic practitioners used for centuries. It’s a concentrated, standardized, mass-produced extract with wildly inconsistent sourcing and zero pre-market safety review.
Prioritize root-extract products. Look for labels that specify “root extract” or carry a branded designation like KSM-66 or Sensoril. Both have published human clinical trials, defined withanolide percentages, and root-only sourcing. Avoid anything labeled “whole plant” or “leaf extract” without strong justification.
Look for third-party certification. USP Verified, NSF Certified for Sport, or Informed Sport marks mean an independent laboratory has confirmed the product contains what it claims and has screened for common contaminants. According to testing data from Qalitex Laboratories, a significant proportion of dietary supplements on the US market fail label accuracy checks — certification is one of the few ways consumers can partially close that information gap.
Stay within the studied dose range. Most trials showing genuine adaptogenic benefits — and most showing acceptable tolerability — used 300–600 mg/day of standardized root extract. Higher doses haven’t been validated for long-term safety, and “more” isn’t a concept that translates linearly to benefit with herbal compounds.
Take periodic breaks. Traditional Ayurvedic practice recommended cycled use of adaptogens rather than indefinite daily supplementation. The long-term safety of continuous ashwagandha use simply hasn’t been formally studied, and intermittent breaks give your liver the chance to clear.
Be honest with your doctor. A 2022 JAMA study found that only 24% of supplement users proactively disclose what they’re taking to their healthcare providers. If you get routine bloodwork, ask for a liver panel — ALT and AST levels are an early warning system that costs almost nothing to run, and knowing your baseline before you start any new supplement is basic harm reduction.
The ashwagandha market is growing fast, and most of the products in it aren’t third-party tested, aren’t transparently sourced, and aren’t formulated based on the clinical research. That’s the real problem: not the herb, but the gap between what traditional use actually looked like and what’s sitting on the supplement aisle shelf today.
If you’re using ashwagandha and feeling fine, that’s genuinely good news. But “feeling fine” isn’t the same as “no effect on liver enzymes” — and the only way to know the difference is to ask your doctor to check.
Written by Nour Abochama, Host & Quality Control Expert, Nourify & Beautify. Learn more about our team
Have questions about product safety? Talk to our experts. Contact us
Related from our network
- What Third-Party Supplement Certification Actually Tests For — Qalitex Laboratories breaks down ISO 17025-accredited testing methods and what USP, NSF, and Informed Sport certifications really verify about your supplement.
- Botanical Raw Material Qualification: Why Ingredient Sourcing Determines Everything — Ayah Labs explains how upstream supplier qualification and identity testing catch adulterated or misidentified botanicals before they reach the finished product stage.
